1. Home
  2. SCLX vs CIF Comparison

SCLX vs CIF Comparison

Compare SCLX & CIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • CIF
  • Stock Information
  • Founded
  • SCLX 2011
  • CIF 1988
  • Country
  • SCLX United States
  • CIF United States
  • Employees
  • SCLX N/A
  • CIF N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • CIF Trusts Except Educational Religious and Charitable
  • Sector
  • SCLX Health Care
  • CIF Finance
  • Exchange
  • SCLX Nasdaq
  • CIF Nasdaq
  • Market Cap
  • SCLX 33.9M
  • CIF 30.8M
  • IPO Year
  • SCLX N/A
  • CIF N/A
  • Fundamental
  • Price
  • SCLX $5.70
  • CIF $1.74
  • Analyst Decision
  • SCLX Strong Buy
  • CIF
  • Analyst Count
  • SCLX 3
  • CIF 0
  • Target Price
  • SCLX $367.50
  • CIF N/A
  • AVG Volume (30 Days)
  • SCLX 125.0K
  • CIF 43.9K
  • Earning Date
  • SCLX 08-12-2025
  • CIF 01-01-0001
  • Dividend Yield
  • SCLX N/A
  • CIF 10.11%
  • EPS Growth
  • SCLX N/A
  • CIF N/A
  • EPS
  • SCLX N/A
  • CIF N/A
  • Revenue
  • SCLX $50,710,000.00
  • CIF N/A
  • Revenue This Year
  • SCLX $107.00
  • CIF N/A
  • Revenue Next Year
  • SCLX $82.52
  • CIF N/A
  • P/E Ratio
  • SCLX N/A
  • CIF N/A
  • Revenue Growth
  • SCLX 7.79
  • CIF N/A
  • 52 Week Low
  • SCLX $3.60
  • CIF $1.47
  • 52 Week High
  • SCLX $78.05
  • CIF $1.77
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 49.86
  • CIF 59.43
  • Support Level
  • SCLX $4.53
  • CIF $1.69
  • Resistance Level
  • SCLX $5.60
  • CIF $1.75
  • Average True Range (ATR)
  • SCLX 0.41
  • CIF 0.01
  • MACD
  • SCLX 0.01
  • CIF 0.00
  • Stochastic Oscillator
  • SCLX 31.96
  • CIF 83.33

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About CIF MFS Intermediate High Income Fund

Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.

Share on Social Networks: